4000-520-616
欢迎来到免疫在线!(蚂蚁淘生物旗下平台)  请登录 |  免费注册 |  询价篮
主营:主营:临床生物学、分子生物学、实验室设备、耗材、免疫学及免疫血液等
咨询热线电话
4000-520-616
当前位置: 首页 > 产品中心 > cytokine > Biovendor/APRIL人类Hi-5昆虫细胞/RBG10066100/100μg
商品详细Biovendor/APRIL人类Hi-5昆虫细胞/RBG10066100/100μg
Biovendor/APRIL人类Hi-5昆虫细胞/RBG10066100/100μg
Biovendor/APRIL人类Hi-5昆虫细胞/RBG10066100/100μg
商品编号: RBG10066100
市场价: ¥20800.00
美元价: 12480.00
产地: 美国(厂家直采)
公司:
产品分类: 细胞因子
公司分类: cytokine
联系Q Q: 3392242852
电话号码: 4000-520-616
电子邮箱: info@ebiomall.com
商品介绍
  • Regulatory status:RUO
  • Type:Recombinant
  • Source:Hi-5 Insect cells
  • Other names:TNF 13, TALL 2, TRDL 1, CD256 antigen , A Proliferation-Inducing Ligand, TNFSF13, TRDL-1α
  • Species:Human

Type

Recombinant

Description

APRIL, a member of the TNF superfamily, is expressed in monocytes, macrophages, certain transformed cell lines, certain cancers of the colon, and lymphoid tissues. APRIL, along with another TNF family member, BAFF, competes for two receptors, TACI and BCMA. APRIL has the ability to stimulate proliferation of various tumor cell lines, including Jurkat T cells and MCF-7 carcinoma cells. Like BAFF, APRIL also stimulates the proliferation of B and T cells. The human APRIL gene codes for at least four alternatively spliced transcriptional variants, which give rise to different isoforms of the APRIL precursor protein. All isoforms can be cleaved by the protease, furin, to release a soluble C-terminal fragment, which comprises the TNF-like receptor binding of the APRIL precursor. Recombinant human APRIL is a soluble 16.3 kDa protein, consisting of 146 amino acid residues.

Amino Acid Sequence

AVLTQKQKKQHSVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRCIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVIIPRARAKLNLSPHGTFLGFVKL

Source

Hi-5 Insect cells

Purity

95%

Biological Activity

Measured by its ability to induce cell death in Jurkat cells.

Storage/Expiration

 –20°C

品牌介绍
miREIA是一种基于免疫测定的新型miRNA定量方法,涉及从患者样品中分离出的miRNA与互补的生物素化DNA寡核苷酸探针杂交。然后通过固定有完美匹配的DNA / miRNA杂交体的微量滴定板固定的单克隆抗体捕获DNA / RNA杂交体。下一步是复制标准ELISA方案。该测定可在常规免疫测定设备上运行,与标准临床工作流程兼容,不需要扩增步骤,并且包括miRNA分析在内的结果可在不到三个小时的时间内获得。